New drug CMAB017 enters human trials for Hard-to-Treat cancers

NCT ID NCT06933069

Recruiting now Disease control Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests a new drug called CMAB017 in 55 people with advanced solid tumors (like head and neck cancer or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also look for any signs that the drug shrinks tumors, but this is not the primary focus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CMAB017 (a drug given by intravenous infusion)
What this could lead to: If this trial shows CMAB017 is safe and has anti-tumor activity, it could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early Phase 1 trial with only 55 participants, so the main goal is safety, not effectiveness. The drug may not shrink tumors or could cause side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID MALIGNANCIES

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, 200123, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.